Amerisourcebergen Corp
LSE:0HF3
Amerisourcebergen Corp
Net Income
Amerisourcebergen Corp
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
Amerisourcebergen Corp
LSE:0HF3
|
Net Income
$1.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
19%
|
|
Cardinal Health Inc
NYSE:CAH
|
Net Income
$1.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
||
Henry Schein Inc
NASDAQ:HSIC
|
Net Income
$319m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-4%
|
||
Patterson Companies Inc
NASDAQ:PDCO
|
Net Income
$168.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-2%
|
||
Mckesson Corp
NYSE:MCK
|
Net Income
$2.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
||
Cencora Inc
NYSE:COR
|
Net Income
$1.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
19%
|
Amerisourcebergen Corp
Glance View
AmerisourceBergen Corp. is a leading healthcare services company that plays an essential role in the pharmaceutical supply chain, connecting manufacturers, healthcare providers, and patients. Founded in 2001 and headquartered in Chesterbrook, Pennsylvania, the company has grown through strategic acquisitions and an unwavering commitment to improving patient access to critical medications. AmerisourceBergen stands out by providing a wide range of services, including drug distribution, specialty pharmacy solutions, and healthcare consulting, making it a vital partner for thousands of healthcare organizations across the United States and beyond. By prioritizing innovation and efficiency, they not only streamline pharmaceutical delivery but also enhance patient care in an increasingly complex healthcare landscape. As investors consider AmerisourceBergen, they can take comfort in the company’s impressive financial performance and resilience against market fluctuations. With a robust revenue stream primarily generated from the distribution of pharmaceuticals, AmerisourceBergen benefits from the growing demand for healthcare products and services. Additionally, the company's strategic partnerships and investment in technology position it well for future growth, particularly in the specialty drug sector, which is expanding rapidly due to the rise of biologics and personalized medicine. AmerisourceBergen's focus on operational excellence and customer satisfaction not only fosters loyalty among its clients but also supports a stable and attractive investment outlook, making it a compelling option for those looking to capitalize on the evolving healthcare market.
See Also
What is Amerisourcebergen Corp's Net Income?
Net Income
1.5B
USD
Based on the financial report for Sep 30, 2024, Amerisourcebergen Corp's Net Income amounts to 1.5B USD.
What is Amerisourcebergen Corp's Net Income growth rate?
Net Income CAGR 10Y
19%
Over the last year, the Net Income growth was -12%. The average annual Net Income growth rates for Amerisourcebergen Corp have been -1% over the past three years , 12% over the past five years , and 19% over the past ten years .